Ling et al. advised that anti-VEGF therapy is a risk factor for PAR in 6- to 8-year-olds and that 32% of their patients with ROP have PAR after anti-VEGF therapy [15]. This evidence concerns the gene VEGFA and retinopathy of prematurity.